Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE: TMC278 vs Efavirenz in Treatment-Naive HIV-1
NCT00543725Phase 3Completed
- Sponsor
- Tibotec
- Start
- Jun 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Tibotec. Primary endpoint: Proportion of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response, <50 Copies Per mL) at 48 weeks. Started Jun 2008; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00543725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543725.